mRNA Victoria’s Post

ImmunoGen, Inc. is now part of AbbVie. This #acquisition accelerates our presence in the #SolidTumor space, and together, we'll advance our combined missions to deliver innovative #cancer therapies. Learn more: https://bit.ly/49xkBmA $ABBV [Video description: On-screen text reads, "ImmunoGen is now part of AbbVie" followed by the AbbVie and ImmunoGen logos. Text continues, "Expanding our oncology portfolio to deliver potentially transformative programs across multiple solid tumors and hematologic malignancies."]

Scancell Holdings sets ambitious roadmap for the next 18 months @scancellpharma #AIM #OTC #SCLP #SCNLF. Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has rolled out its roadmap for the next 18 months, which builds on the significant clinical progress made to date. An early milestone comes from the release of full cohort data for SCIB1 and iSCIB1+ (for melanoma) in late 2024 and early 2025. The cancer immunotherapy specialist also plans to launch a phase II/III registration trial for SCIB1 or iSCIB1+ in 2025. In the first stage of the phase II study of SCIB1, 11 out of 13 patients achieved at least a partial response, exceeding the 70% overall response rate the... http://ow.ly/HivJ105JH51

We announced a poster presentation of data from the first-in-human, global, multi-center, phase 1a/1b study of CS5001 (ROR1 ADC), one of the key assets in CStone Pipeline 2.0, in patients with advanced solid tumors and lymphomas at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The latest first-in-human study data show that CS5001 is well tolerated with promising anti-tumor activity at various dose levels in heavily pretreated, advanced solid tumors and lymphomas. CS5001 is the first known ROR1 ADC to demonstrate clinical anti-tumor activity in both solid tumors and lymphomas. Read more here: https://lnkd.in/gGm9-J9E

Evaluate your therapeutics' potency in Champions' NSCLC TumorGraft3D Screen, utilizing our unique matrix-free platform. Obtain essential results to prioritize models for your IND-enabling in vivo studies. This screen features EGFR-mutant and KRAS-mutant models, EGFR+ MET+ models, and models with acquired resistance to osimertinib. These NSCLC models are well characterized with industry-leading clinical annotation and patients' treatment responses. Enroll before April 12th, 2024, to assess your therapeutics' response in this 3D screen: https://hubs.li/Q02kh2xw0 #TumorGraft3D #NSCLC #LungCancer #3D #OncologyResearch #organoids #CancerResearch #Cancer #Oncology #Screen #EGFR #KRAS #osimertinib #MET

In view of the clinical problem of high recurrence and metastasis rate of triple-negative breast cancer, it is proposed to construct a nano-activator that can enhance microwave thermodynamic-chemotherapy to effectively kill the primary tumor and improve the immunosuppressive microenvironment at the same time. A MOF-based MPPT nanoactivator was constructed by encapsulating the chemotherapy drug Pyrotinib and the immunosuppressant PD-1/PD-L1 inhibitor 2 into MnCa-metal organic framework (MOF), and further coupling the targeting molecule triphenyl phosphine to significantly improve the aggregation and penetration of Pyrotinib and immunosuppressants in tumors. https://lnkd.in/gFwk8t3v

Alectinib Shows Promise as Adjuvant Therapy in NSCLC Alectinib is a targeted Tyrosine Kinase Inhibitor that is being evaluated as an adjuvant therapy in Non Small Cell Lung Cancer patients, who were positive for ALK mutations, following resection of tumors. The current SOC for these patients is Platinum Chemotherapy. In this Phase 3 clinical trial Alectinib showed significant clinical benefit for disease free survival and moderate adverse events (following twice daily for 24 months) when compared to Platinum chemotherapy. Clearly the targeted therapy showed significantly better activity when compared to chemotherapy. Whether this will translate to better Overall survival in these patients remains to be seen. https://lnkd.in/gPT4M_B6

NIAGARA phase III trial of AstraZeneca’s Imfinzi demonstrates statistically significant and clinically meaningful improvement in EFS and OS for muscle-invasive bladder cancer

For National Cancer Research Month, we want to say thank you to our team and the researchers, clinicians, and patients who are taking part in clinical trials to advance new therapeutics. We've made important progress, but there is still much to be done. Together, we can push forward and make a difference in the lives of those affected by #cancer. Learn more about our #clinicaltrials and the contributions Janux is making to #cancerresearch: https://lnkd.in/ggvVSxn3 #NCRM24 #CancerResearchSavesLives #TCellEngagers #cancer #oncology #immunotherapy #immunomodulators

AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients With MTAP-Deleted Cancers. Discovery of the clinical stage MTA-cooperative PRMT5 inhibitor AMG 193, which preferentially binds PRMT5 in the presence of MTA and has potent biochemical and cellular activity in MTAP-deleted cells across multiple cancer lineages. AMG 193 is demonstrating promising clinical activity, including confirmed partial responses in patients with MTAP-deleted solid tumors from an ongoing phase 1/2 study. https://lnkd.in/g43zvaiU

𝐄𝐧𝐡𝐞𝐫𝐭𝐮 𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 𝐢𝐧 𝐂𝐡𝐢𝐧𝐚 as the 𝐟𝐢𝐫𝐬𝐭 𝐇𝐄𝐑2-𝐝𝐢𝐫𝐞𝐜𝐭𝐞𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 for patients with HER2-mutant metastatic NSCLC 📢 𝐊𝐞𝐲 𝐎𝐛𝐬𝐞𝐫𝐯𝐚𝐭𝐢𝐨𝐧 📍 𝐂𝐨𝐧𝐝𝐢𝐭𝐢𝐨𝐧𝐚𝐥 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥: Approval is based on the DESTINY-Lung02 (Global Trial) and DESTINY-Lung05 (China Specific) Phase II trials 📍𝐄𝐬𝐭𝐚𝐛𝐥𝐢𝐬𝐡𝐞𝐝 𝐃𝐫𝐮𝐠 𝐟𝐨𝐫 𝐍𝐒𝐂𝐋: Already approved for previously treated unresectable/metastatic HER2-mutant NSCLC in more than 45 countries, including the US, Japan and across the EU 📍𝐄𝐧𝐡𝐞𝐫𝐭𝐮 𝐚𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐢𝐧 𝐂𝐡𝐢𝐧𝐚: This counts 4th approval of Enhertu in China across three different tumor types AstraZeneca Daiichi Sankyo US #NSCLC #Oncology #Cancer #Approval